Hinge Health (HNGE) CFO budge sells $4.9m in common shares

James Budge, Chief Financial Officer at Hinge Health, Inc. (NASDAQ:HNGE), sold 47,720 shares of the company’s Class A common stock on October 12, 2026. The transactions totaled $4,921,577, with shares sold at prices ranging from $101.00 to $104.72 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan that Mr. Budge adopted on June 11, 2026.

Specifically, Mr. Budge disposed of shares in multiple tranches. This included 2,100 shares at a weighted average price of $101.5272, 21,702 shares at $102.5381, 14,498 shares at $103.48, and 9,420 shares at $104.335.

Following these transactions, Mr. Budge directly holds 296,728 shares of Hinge Health Class A common stock.The sale comes as Hinge Health stock trades near its 52-week high of $107, following a remarkable 178% surge over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, which investors can explore further on the Most Overvalued stocks list. For deeper insights into Hinge Health’s valuation and growth prospects, the comprehensive Pro Research Report—available for this and 1,400+ other US equities—transforms complex data into actionable intelligence.

In other recent news, Hinge Health has been the focus of various analyst updates and projections. Stifel raised its price target for the company to $115, citing a strong growth outlook with an expected 2027 growth of over 33%, surpassing the consensus estimate of 27%. Truist Securities also revised its financial model for Hinge Health, increasing its price target to $112 from $85, following the company’s second-quarter earnings results and the pending acquisition of Cylinder Health. Truist now anticipates revenue to reach $860 million for fiscal 2026 and $1,095 million for fiscal 2027.

Additionally, BofA Securities initiated coverage on Hinge Health with a Buy rating and a price target of $110. The firm set this target based on a 22x CY27E EV/FCF multiple. Truist Securities reiterated its Buy rating on the stock, emphasizing a strong selling season after meetings with company executives. Meanwhile, Stifel previously raised its price target to $96, acknowledging the company’s outperformance in a pre-release announcement. These developments reflect a positive sentiment among analysts regarding Hinge Health’s future performance.